• Remibrutinib Significantly Reduces Relapse Rate and Shows Favorable Safety in Phase III Trial for New Indication in Relapsing Multiple Sclerosis (RMS)

  On September 1, 2026, local time, Novartis announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials of remibrutinib in rel···【Read More】

  Update: 07 Sep,2026Source: BigbearViews: 106

• Zanvastro (zilganersen) Approved in the U.S. for the Treatment of Rare Alexander Disease

  On September 3, 2026, the U.S. Food and Drug Administration (FDA) approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in···【Read More】

  Update: 04 Sep,2026Source: BigbearViews: 114

• FDA has approved Lytenava (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD)

  On July 24, 2026 local time, Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Lytenava (bevacizumab-···【Read More】

  Update: 03 Aug,2026Source: BigbearViews: 128

• FDA approves Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease!

  Local time June 26, 2026, Viridian Therapeutics, Inc., a biotechnology company focused on discovering, developing, and commercializing potential best-···【Read More】

  Update: 01 Jul,2026Source: BigbearViews: 211

• Sanofi’s Tzield Approved in the US as the First Disease-Modifying Therapy for Patients Recently Diagnosed with Stage 3 Type 1 Diabetes

  Paris, June 13, 2026. The US Food and Drug Administration (FDA) has granted accelerated approval to Tzield (teplizumab-mzwv) to delay the decline in e···【Read More】

  Update: 16 Jun,2026Source: BigbearViews: 244

• FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

  On 15 May 2026, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) and atezolizumab and hyaluronidase-tqjs (···【Read More】

  Update: 12 Jun,2026Source: BigbearViews: 288

• FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

  June 9, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for EBGLYSS (lebriki···【Read More】

  Update: 10 Jun,2026Source: BigbearViews: 269

• Autobahn accelerates toward pivotal clinical trials: Thyroid hormone mimetic relieves bipolar depression in phase 2 trial

  Elunetirom is a small molecule drug taken orally once daily. After six weeks of treatment, patients' depression severity decreased by an average o···【Read More】

  Update: 05 Jun,2026Source: BigbearViews: 259

• FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections

  May 30, 2026 – Wockhardt announced that the U.S. Food and Drug Administration (FDA) has approved Zaynich (cefepime and zidebactam), a novel intravenou···【Read More】

  Update: 03 Jun,2026Source: BigbearViews: 296

• EMA Recommends Extending Indications for Decitabine /Cedazuridine

  On 23 April 2026, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommendi···【Read More】

  Update: 01 Jun,2026Source: BigbearViews: 274

• FDA Approves Use of Linzess (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

  May 27, 2026 -- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for peop···【Read More】

  Update: 28 May,2026Source: BigbearViews: 208

• FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  May 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Decnupaz (pivekimab sun···【Read More】

  Update: 28 May,2026Source: BigbearViews: 226

• FDA approves the first all-oral combination regimen for patients with acute myeloid leukemia who cannot tolerate intensive induction chemotherapy

  On May 13, 2026, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved decit···【Read More】

  Update: 27 May,2026Source: BigbearViews: 181

• FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) Treatment for Chronic Hepatitis Delta Virus (HDV)

  FOSTER CITY, Calif.--(BUSINESS WIRE) May 22, 2026 -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (···【Read More】

  Update: 25 May,2026Source: BigbearViews: 196

• FDA Approves Inqovi for Acute Myeloid Leukemia

  FRIDAY, May 22, 2026 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of a···【Read More】

  Update: 25 May,2026Source: BigbearViews: 211